Perindopril is an inhibitor of angiotensin-I converting enzyme (ACE) [1].

As an inhibitor of ACE, perindopril has been reported to have anticancer activity through the inhibition of tumor growth and angiogenesis in hepatocellular carcinoma cells. In the in vitro cell proliferation assays, perindopril does not show significant effect on the cell proliferation. However, even 1μM perindoprilat can significantly reduce mRNA expression of VEGF and can inhibit the induction activity of the VEGF promoter in KB cells. Also in KB cells, 1μM perindoprilat treatment significantly suppresses the angiotensin II production. Besides that, In vivo assays demonstrate perindopril can suppress the growth of SCC-VII cells [1]. Moreover, it is reported that 8 mg perindopril given orally can lower blood pressure without a change in heart rate [1, 2].

References:
[1] Ryuji Yasumatsu, Torahiko Nakashima, Muneyuki Masuda, Aya Ito, Yuichiro Kuratomi, Yuichiro Kuratomi and Shizuo Komune. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2004, 130: 567–573.
[2] A.A.Ajayi, K.R.Lees and J.L.Reid. Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. Eur J Clin Pharmacol. 1986, 30:177-182.